World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
43
Citations
7054
World Ranking
4847
National Ranking
405

Overview

Aymen Al-Shamkhani is affiliated with the University of Southampton in the United Kingdom. Their research focus spans immunology and microbiology as well as medicine, with significant contributions across related subfields including immunology, oncology, radiology, nuclear medicine and imaging, epidemiology, and molecular biology.

The scientist's work addresses key topics within immunotherapy and immune responses, immune cell function and interaction, monoclonal and polyclonal antibodies research, cancer immunotherapy and biomarkers, T-cell and B-cell immunology, CAR-T cell therapy research, and nonmelanoma skin cancer studies.

Frequent publication venues for their research include the Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), Cancer Research, and JCI Insight.

Among their recent papers are the following:

  • NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors, 2020, Cancer Research
  • CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma, 2021, Journal for ImmunoTherapy of Cancer
  • Domain binding and isotype dictate the activity of anti-human OX40 antibodies, 2020, Journal for ImmunoTherapy of Cancer
  • Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors, 2021, Journal for ImmunoTherapy of Cancer
  • Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges, 2023, Clinical Cancer Research

Collaborators frequently working with Aymen Al-Shamkhani include Mark S. Cragg, Jinny Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, and Martin J. Glennie.

Best Publications

  • Viral infection switches non-plasmacytoid dendritic cells into high interferon producers

    Sandra S Diebold;Maria Montoya;Hermann Unger;Lena Alexopoulou

  • NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors

    Kirsty Ford;Christopher J Hanley;Massimiliano Mellone;Cedric Szyndralewiez

  • Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

    Michael A. Curran;Myoungjoo Kim;Welby Montalvo;Aymen Al-Shamkhani

  • CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice.

    V Malmström;D Shipton;B Singh;A Al-Shamkhani

  • The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy

    Sarah L. Buchan;Anne Rogel;Aymen Al-Shamkhani

  • Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

    Ann L. White;H. T. Claude Chan;Ali Roghanian;Ruth R. French

  • Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.

    Vadim Y. Taraban;Tania F. Rowley;Lyn O'Brien;H. T. Claude Chan

  • Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

    Michael A. Curran;Theresa L. Geiger;Welby Montalvo;Myoungjoo Kim

  • Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

    Ann L. White;H.T. Claude Chan;Ruth R. French;Jane E. Willoughby

  • Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation

    Ruth R. French;Vadim Y. Taraban;Graham R. Crowther;Tania F. Rowley

  • Cutting Edge: A Critical Role for CD70 in CD8 T Cell Priming by CD40-Licensed APCs

    Vadim Y. Taraban;Tania F. Rowley;Aymen Al-Shamkhani

  • Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154

    Linsey E. Haswell;Martin J. Glennie;Aymen Al-Shamkhani

  • OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.

    A al-Shamkhani;M L Birkeland;M Puklavec;M H Brown

  • The Death Receptor 3–TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis

    Melanie Jane Bull;Anwen Siân Williams;Zarabeth Mecklenburgh;Claudia Jane Calder

  • Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo.

    Tania F. Rowley;Aymen Al-Shamkhani

  • Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.

    Sarah L. Buchan;Lang Dou;Marcus Remer;Steven G. Booth

  • Dysregulation of Antiviral Function of CD8+ T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1–PD-L1 Axis

    Richard T. McKendry;C. Mirella Spalluto;Hannah Burke;Ben Nicholas

  • A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens.

    Pooja Arora;Andres Baena;Karl O.A. Yu;Neeraj K. Saini

  • The TNF-Family Ligand TL1A and Its Receptor DR3 Promote T Cell–Mediated Allergic Immunopathology by Enhancing Differentiation and Pathogenicity of IL-9–Producing T Cells

    Arianne C. Richard;Cuiyan Tan;Eric T. Hawley;Julio Gomez-Rodriguez

  • PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.

    Sarah L. Buchan;Mohannad Fallatah;Stephen M. Thirdborough;Vadim Y. Taraban

  • antibody therapy is critically dependent on CD27 costimulation Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal

    Alison L. Tutt;Aymen Al-Shamkhani;Martin J. Glennie;Ruth R. French

Frequent Co-Authors

Martin J. Glennie
Martin J. Glennie University of Southampton
Mark S. Cragg
Mark S. Cragg University of Southampton
Eugene Healy
Eugene Healy University of Southampton
Peter Johnson
Peter Johnson University of Southampton
Edward Chung Yern Wang
Edward Chung Yern Wang Cardiff University
James P. Allison
James P. Allison The University of Texas MD Anderson Cancer Center
Richard M. Siegel
Richard M. Siegel National Institutes of Health
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center
Tim Elliott
Tim Elliott University of Southampton
Salim I. Khakoo
Salim I. Khakoo University of Southampton

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare fields such as nursing practitioner programs offer valuable career alternatives. When exploring these options, it’s important to consider program flexibility; many students seek the easiest nurse practitioner program to balance studies with other commitments without compromising quality.

Mental health is another growing specialty, and aspiring professionals should carefully select programs known for strong clinical training. The top pmhnp programs highlight institutions with superb clinical placement rates, ensuring hands-on experience essential for success.

Cost is often a deciding factor; prospective students can find affordable pathways through the cheapest psychiatric nurse practitioner programs, which help reduce financial barriers to advanced education.

Finally, understanding potential earnings after graduation is crucial for career planning. Resources outlining how much a DNP makes provide insights into salary expectations across states, helping guide informed decisions about where to study and work.

Best Scientists Citing Aymen Al-Shamkhani

Trending Scientists